Endocrine-disrupting chemicals (EDCs) encompass a class of substances capable of interfering with the endocrine system, thereby inducing diseases and functional irregularities in organisms. These ...

Younger age at diagnosis, prior primary hyperparathyroidism, non-missense pathogenic variants, and female sex increase the ...

(Beyond Pesticides, October 8, 2024) A comprehensive literature review in Endocrines, published in September, amasses hundreds of studies on endocrine-disrupting chemicals (EDCs) that showcase adverse ...

In a recent study published in Hypertension Research, scientists examine the endocrine causes of hypertension (HTN) and investigate the efficacy of treatments to alleviate HTN. Study: Endocrine causes ...

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma These data represent an ...

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 ...

Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. We conducted a ...

In a previous post, I discussed the connection between the mind and the skin. In that article, I called for patients and clinicians to become more aware of the relationship between cutaneous and ...

The novel system being used in the study was cleared by the Food & Drug Administration in 2024 for ablation of soft tissue ...